Resource Type

Journal Article 23

Year

2023 1

2022 4

2021 4

2020 2

2019 4

2017 1

2015 1

2014 2

2011 1

2010 2

2009 1

open ︾

Keywords

Alzheimer’s disease 2

Zika virus 2

immune checkpoint inhibitor 2

immunotherapy 2

FLT3 inhibitors 1

AMLTargeted therapy 1

CAR T-cell therapy 1

COVID-19 1

China 1

D loop 1

DFT 1

EGFR inhibitor 1

Ebola virus 1

Gilteritinib 1

HMG-CoA reductase inhibitor 1

His-Purkinje pacing 1

IL-17 1

Leu309 demethylation 1

Midostaurin 1

PD-L1 1

open ︾

Search scope:

排序： Display mode:

Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection

Weibao Song, Hongjuan Zhang, Yu Zhang, Rui Li, Yanxing Han, Yuan Lin, Jiandong Jiang

Frontiers of Medicine 2021, Volume 15, Issue 3,   Pages 404-415 doi: 10.1007/s11684-021-0834-9

Abstract: Zika virus (ZIKV) is an emerging pathogen associated with neurological complications, such as Guillain–BarréHowever, the development of antivirals against ZIKV is lagging.Although various strategies have been used to study anti-ZIKV agents, approved drugs or vaccines forthe treatment (or prevention) of ZIKV infections are currently unavailable.Their characteristics, targets, and potential use in anti-ZIKV therapy are presented.

Keywords： Zika virus     clinical drugs     ZIKV inhibitors     antivirals     repurposing    

HTML PDF Collect

Atomistic characterization of binding modes and affinity of peptide inhibitors to amyloid-

Fufeng LIU,Wenjie DU,Yan SUN,Jie ZHENG,Xiaoyan DONG

Frontiers of Chemical Science and Engineering 2014, Volume 8, Issue 4,   Pages 433-444 doi: 10.1007/s11705-014-1454-6

Abstract: Previous studies have found that three peptide inhibitors (i.e., KLVFF, VVIA, and LPFFD) can inhibitHowever, atomic details of binding modes and binding affinities between these peptide inhibitors andAll inhibitors exhibit varied binding affinity to A , in which KLVFF has the highest binding affinityMM/PBSA analysis further revealed that different peptide inhibitors have different modes of interactionSpecific residue-based interactions between inhibitors and A were determined and compared for illustrating

Keywords： Alzheimer’s disease     amyloid β-protein     peptide inhibitors     protein-protein interaction     molecular    

HTML PDF Collect

Synthesis of mono and bis-4-methylpiperidiniummethyl-urea as corrosion inhibitors for steel in acidic

Abbas TEIMOURI, Nasrin SOLTANI, Alireza Najafi CHERMAHINI

Frontiers of Chemical Science and Engineering 2011, Volume 5, Issue 1,   Pages 43-50 doi: 10.1007/s11705-010-0532-7

Abstract: Mono and bis-4-methylpiperidiniummethyl urea were synthesized, characterized and used as new corrosion inhibitorsPotentiodynamic polarization measurements showed that two inhibitors are mixed type.This reveals that inhibitive actions of inhibitors were mainly due to adsorption on mild steel surface

Keywords： corrosion inhibitors     mild steel     acidic medium     theoretical studies     DFT    

HTML PDF Collect

Mitogen-activated protein kinase pathway inhibitors: inhibitors for diseases?

Xu WANG MS, Xiao-Wei GONG MD, PhD, Yong JIANG MD, PhD, Yu-Hua LI PhD,

Frontiers of Medicine 2010, Volume 4, Issue 1,   Pages 46-53 doi: 10.1007/s11684-010-0010-0

Abstract: So far, inhibitors specifically against each subfamilies of MAP kinase have been developed, while moreMost of the kinase inhibitors exert their functions in an ATP-competitive way or a non-ATP-competitiveFurther studies on the effective mechanism of the MAPK inhibitors and their therapeutic roles in thetreatment of diseases are helpful for the illumination of MAP kinase function, the development of novel inhibitors

Keywords： mitogen-activated protein kinase     drug target     inhibitor     signal transduction     disease    

HTML PDF Collect

Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases

Zhen Xiang, Yingyan Yu

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 24-31 doi: 10.1007/s11684-019-0679-7

Abstract: Immune checkpoint inhibitors are a promising strategy in the treatment of cancer, especially advancedHowever, not all patients are responsive to immune checkpoint inhibitors.of data, which allow researchers to explore responsive or resistant biomarkers of immune checkpoint inhibitors

Keywords： immune checkpoint blockade     sensitivity     resistance     data mining    

HTML PDF Collect

Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 307-321 doi: 10.1007/s11684-022-0927-0

Abstract: The discovery of immune checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4, has played an importantwidely applied in clinical treatment, and they are inevitably used in combination with immune checkpoint inhibitorsClinical practice has revealed that antibiotics can weaken the therapeutic response to immune checkpoint inhibitorsStudies have shown that the gut microbiota is essential for the interaction between immune checkpoint inhibitorsThis review focuses on the interactions between immune checkpoint inhibitors and antibiotics, with an

Keywords： tumor immunotherapy     immune checkpoint inhibitor     antibiotics     gut microbiota     drug–drug interaction    

HTML PDF Collect

Advances in newly developing therapy for chronic hepatitis C virus infection

Paul J. Pockros

Frontiers of Medicine 2014, Volume 8, Issue 2,   Pages 166-174 doi: 10.1007/s11684-014-0334-2

Abstract:

Chronic hepatitis C virus (HCV) infection afflicts a reported 170 million people worldwide and is often complicated by cirrhosis and hepatocellular carcinoma. Morbidity and mortality are decreased with the successful treatment of chronic HCV infection. Increased understanding of the HCV has allowed further development of new direct-acting antiviral (DAA) agents against the HCV and has also allowed the development of IFN-free oral treatment regimens. In late 2013 the first nucleotide polymerase inhibitor regimen with RBV alone for genotypes 2/3 and in combination with a 12-week regimen of PEG-IFN+RBV for genotypes 1, 4 was approved for use in the US. A number of promising new DAA regimens which are IFN-free are in phase 3 development and the first will likely be approved for use in the US in 2014. The currently approved regimens are discussed in detail and currently available data on future regimens are reviewed herein.

Keywords： direct-acting antiviral (DAA)     nucleotide polymerase inhibitors     protease inhibitors    

HTML PDF Collect

DISCOVERY OF TRIKETONE-QUINOXALINE HYBRIDS AS POTENT HPPD INHIBITORS USING STRUCTURE-BASED DRUG DESIGN

Frontiers of Agricultural Science and Engineering 2022, Volume 9, Issue 1,   Pages 133-145 doi: 10.15302/J-FASE-2021401

Abstract: This study indicates that triketone-quinoxaline is a promising scaffold for discovering HPPD inhibitors

Keywords： herbicide / HPPD / inhibitor / quinoxaline / triketon    

HTML PDF Collect

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 32-44 doi: 10.1007/s11684-018-0678-0

Abstract: In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overall

Keywords： immune checkpoint     companion diagnosis     PD-L1     tumor mutation burden     immune score    

HTML PDF Collect

Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging

Xiaohuan Wang, Peng Zou, Fan Wu, Lu Lu, Shibo Jiang

Frontiers of Medicine 2017, Volume 11, Issue 4,   Pages 449-461 doi: 10.1007/s11684-017-0589-5

Abstract: this review, we summarize and discuss the latest progress in the development of small-molecule viral inhibitorsWe also discuss some general strategies for developing small-molecule viral inhibitors.

Keywords： emerging and re-emerging viruses     small-molecule inhibitor     coronavirus     Ebola virus     Zika virus     life cycle    

HTML PDF Collect

design of novel proton-pump inhibitors with reduced adverse effects

Xiaoyi Li, Hong Kang, Wensheng Liu, Sarita Singhal, Na Jiao, Yong Wang, Lixin Zhu, Ruixin Zhu

Frontiers of Medicine 2019, Volume 13, Issue 2,   Pages 277-284 doi: 10.1007/s11684-018-0630-3

Abstract: The development of new proton-pump inhibitors (PPIs) with less adverse effects by lowering the pKa values

Keywords： proton-pump inhibitor     adverse effect     pharmacological mechanism     toxicological mechanism     pKa calculation    

HTML PDF Collect

Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 701-713 doi: 10.1007/s11684-022-0951-0

Abstract: inevitable acquired resistance to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

Keywords： acquired resistance     EGFR inhibitor     apoptosis     lung cancer    

HTML PDF Collect

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 689-700 doi: 10.1007/s11684-020-0759-8

Abstract: The cure rate of childhood acute lymphoblastic leukemia (ALL) has exceeded 90% in some contemporary clinical trials. However, the dose intensity of conventional chemotherapy has been pushed to its limit. Further improvement in outcome will need to rely more heavily on molecular therapeutic as well as immuno- and cellular-therapy approaches together with precise risk stratification. Children with or hyperdiploid>50 ALL who achieve negative minimal residual disease during early remission induction are suitable candidates for reduction in treatment. Patients with Philadelphia chromosome (Ph)-positive or Ph-like ALL with ABL-class fusion should be treated with dasatinib. BH3 profiling and other preclinical methods have identified several high-risk subtypes, such as hypodiplod, early T-cell precursor, immature T-cell, -rearranged, Ph-positive and -positive ALL, that may respond to BCL-2 inhibitor venetoclax. There are other fusions or mutations that may serve as putative targets, but effective targeted therapy has yet to be established. For other high-risk patients or poor early treatment responders who do not have targetable genetic lesions, current approaches that offer hope include blinatumomab, inotuzumab and CAR-T cell therapy for B-ALL, and daratumumab and nelarabine for T-ALL. With the expanding therapeutic armamentarium, we should start focus on rational combinations of targeted therapy with non-overlapping toxicities.

Keywords： acute lymphoblastic leukemia     molecular therapeutics     targeted therapy     tyrosine kinase inhibitors     immunotherapy    

HTML PDF Collect

Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 773-783 doi: 10.1007/s11684-021-0902-1

Abstract: The total number of cancer patients who are eligible for and will benefit from immune checkpoint inhibitors

Keywords： benefit     China     eligibility     immune checkpoint inhibitor     public health    

HTML PDF Collect

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions

Frontiers of Medicine 2023, Volume 17, Issue 1,   Pages 18-42 doi: 10.1007/s11684-022-0976-4

Abstract: Furthermore, the therapeutic role of immune-checkpoint inhibitors (ICIs) in oncogene-driven NSCLC remains

Keywords： non-small cell lung cancer     driver mutations     treatment strategy     resistant mechanism     immune-checkpoint inhibitors    

HTML PDF Collect

Title Author Date Type Operation

Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection

Weibao Song, Hongjuan Zhang, Yu Zhang, Rui Li, Yanxing Han, Yuan Lin, Jiandong Jiang

Journal Article

Atomistic characterization of binding modes and affinity of peptide inhibitors to amyloid-

Fufeng LIU,Wenjie DU,Yan SUN,Jie ZHENG,Xiaoyan DONG

Journal Article

Synthesis of mono and bis-4-methylpiperidiniummethyl-urea as corrosion inhibitors for steel in acidic

Abbas TEIMOURI, Nasrin SOLTANI, Alireza Najafi CHERMAHINI

Journal Article

Mitogen-activated protein kinase pathway inhibitors: inhibitors for diseases?

Xu WANG MS, Xiao-Wei GONG MD, PhD, Yong JIANG MD, PhD, Yu-Hua LI PhD,

Journal Article

Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases

Zhen Xiang, Yingyan Yu

Journal Article

Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy

Journal Article

Advances in newly developing therapy for chronic hepatitis C virus infection

Paul J. Pockros

Journal Article

DISCOVERY OF TRIKETONE-QUINOXALINE HYBRIDS AS POTENT HPPD INHIBITORS USING STRUCTURE-BASED DRUG DESIGN

Journal Article

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian

Journal Article

Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging

Xiaohuan Wang, Peng Zou, Fan Wu, Lu Lu, Shibo Jiang

Journal Article

design of novel proton-pump inhibitors with reduced adverse effects

Xiaoyi Li, Hong Kang, Wensheng Liu, Sarita Singhal, Na Jiao, Yong Wang, Lixin Zhu, Ruixin Zhu

Journal Article

Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors

Journal Article

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Journal Article

Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors

Journal Article

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions

Journal Article